Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midazolam plus nitrous oxide sedation versus physical restraint for dental treatment in children with intellectual disabilities
RBR-7dn5w43Phase 4Not yet recruiting
- Sponsor
- Federal University of Rio de Janeiro
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of midazolam and nitrous oxide in intellectual disability (ID) and Autism Spectrum Disorder (ASD) (2 arms), sponsored by Federal University of Rio de Janeiro. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
midazolamnitrous oxide
03
Conditions
intellectual disability (ID)Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on RBR-7dn5w43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-7dn5w43.